KEEPsAKE2NCT03671148
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 28 versions: 25 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 6 words Show 5 more changesShow less
- Sponsor refiled this as active, not recruiting (was completed)
- Study completion date: Jun 4, 2026 to Jan 2029
- Secondary endpoints: details revised at 10 of 10 entries
- Site details revised at 138 of 138 sites
- Publications: details revised at 9 of 9 entries
- Minor Trial status: Active, Not Recruiting to Completed
- Study completion date changed from estimate of Jun 2026 to Jun 4, 2026
- Minor Study completion date: Jun 12, 2026 to Jun 2026v26
- Minor Study completion date: May 18, 2024 to Jun 12, 2026
- Study description revised
- Minor Study completion date: Mar 22, 2024 to May 18, 2024v22
Show 19 earlier versionsHide 19 earlier versions
- Notable Results first posted: Mar 2, 2022v21
Notable Eligibility criteria expanded, about 44 wordsv20 Show 8 more changesShow less
- Primary endpoint revised
- Enrollment target: estimated 420 to confirmed 444
- Study completion date: May 17, 2024 to Mar 22, 2024
- Interventions: placebo for rizankizumab (Biological), risankizumab (Biological) to Placebo (Biological), Risankizumab (Biological)
- Secondary endpoints revised (10)
- Study description expanded, about 131 words
- Study sites revised (138)
- Publications: details revised at 1 of 9 entries
- Minor Enrollment target: 444 to 420
- Study sites revised (138)
Notable Eligibility criteria revisedv17 Show 5 more changesShow less
- Enrollment target: 429 to 444
- Study sites: 139 to 138
- Primary completion date changed from estimate of Jun 19, 2020 to Jun 22, 2020
- Secondary endpoints: 9 to 10
- Study title revised
- Minor Enrollment target: 444 to 429
- Study sites: 143 to 139
- Primary completion date: Jan 29, 2021 to Jun 19, 2020
- Notable Primary completion date: Jun 19, 2020 to Jan 29, 2021
- Primary endpoint revised
- Study sites: 147 to 143
- Secondary endpoints: 7 to 9
- Minor Study sites: 152 to 147v14
Notable Eligibility criteria expanded, about 4 wordsv13 Show 5 more changesShow less
- Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 420 to confirmed 444
- Study sites: 154 to 152
- Primary completion date: Jan 29, 2021 to Jun 19, 2020
- Study completion date: May 16, 2024 to May 17, 2024
- Minor Study sites: 172 to 154
- Study completion date: Dec 27, 2024 to May 16, 2024
- Minor Site details revised at 22 of 172 sitesv11
- Minor Study sites revised (172)v10
- Minor Study sites: 173 to 172v9
- Minor Study sites: 172 to 173v8
- Minor Study sites: 169 to 172v7
- Minor Study sites: 165 to 169v6
- Minor Study sites: 169 to 165v5
- Minor Study sites: 168 to 169
- Start date: Mar 8, 2019 to Mar 7, 2019
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 113 to 168
- Study completion date: Nov 1, 2024 to Dec 27, 2024
- Start date changed from estimate of Feb 22, 2019 to Mar 8, 2019
- Minor Study sites: 0 to 113
- Study completion date: Dec 27, 2024 to Nov 1, 2024
- Start date: Feb 26, 2019 to Feb 22, 2019
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (10)
Show 5 moreShow less
Arms and interventions
Participants randomized to receive 150 mg risankizumab administered by subcutaneous injection at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive blinded placebo followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.
Participants randomized to receive double-blind placebo at Week 0, Week 4, and Week 16 in Period 1. At Week 24 participants will receive 150 mg risankizumab followed by open-label 150 mg risankizumab at Week 28, and every 12 weeks thereafter in Period 2 until the final dosing time point at Week 316.
Biologicals: Placebo, Risankizumab
Sites
138 sites in 25 countries
United States 55, Argentina 7, Australia 5, Canada 5, Israel 5, Poland 5, Spain 5, Belgium 4, Germany 4, Hungary 4, Sweden 4, United Kingdom 4, Estonia 3, Greece 3, Italy 3, Netherlands 3, New Zealand 3, Portugal 3, South Africa 3, Brazil 2, Denmark 2, Finland 2, France 2, Puerto Rico 1, Singapore 1